Tag: Hatch-Waxman Act
14
May 2026
- By Leona Ashfield
- Health
- 11 Comments
Who Makes Authorized Generics? The Hidden Manufacturing Truths
Discover who actually manufactures authorized generics. From in-house production to contract partnerships, explore the hidden supply chains, regulatory pathways, and market strategies behind these lower-priced brand-name drugs.
22
Mar 2026
- By Leona Ashfield
- Health
- 13 Comments
180-Day Exclusivity: How Patent Law Delays Generic Drug Entry
The 180-day exclusivity rule under the Hatch-Waxman Act gives the first generic drug challenger a temporary monopoly, but it's often used to delay market entry - costing patients billions in higher drug prices.
19
Mar 2026
- By Leona Ashfield
- Health
- 13 Comments
Patent Litigation: How Authorized Generics Affect Competition in Drug Markets
Authorized generics are branded drugs sold under generic labels, often launched by the original manufacturer to undercut independent generics. They reduce competition, delay price drops, and are increasingly under regulatory scrutiny for anti-competitive practices.